# bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

> **NCT06070636** · NA · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Liver Diseases
- Hepatocellular Carcinoma
- Immunotherapy
- Lenvatinib
- Sintilimab

## Interventions

- **PROCEDURE:** bTAE-HAIC
- **DRUG:** Lenvatinib
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06070636
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06070636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06070636, "bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06070636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*